Literature DB >> 12079308

Groin recurrence after micrometastasis in a sentinel lymph node in a patient with vulvar cancer.

Karl F Tamussino1, Arnim A Bader, Sigurd F Lax, Reingard M Aigner, Raimund Winter.   

Abstract

BACKGROUND: The sentinel lymph node concept is attractive in vulvar cancer because of the potential to avoid the morbidity associated with formal groin dissection. CASE: An 84-year-old patient with a T2 carcinoma of the anterior vulva underwent surgery including bilateral sentinel node excision after identification with technetium-labeled nanocolloid. Frozen section histology showed a tumor deposit <1 mm in diameter in a left groin node whereas four nodes in the right groin were apparently negative. Completion lymphadenectomy was performed only for the left groin. Final histology including serial sectioning showed a micrometastasis in one of seven nodes from the right groin; no further treatment was given. Sixteen months postoperatively the patient developed a recurrence in the right groin; the left groin was free of tumor.
CONCLUSION: This case indicates that groins with a micrometastasis detected by sentinel lymph node excision require further treatment. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Year:  2002        PMID: 12079308     DOI: 10.1006/gyno.2002.6727

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

Review 1.  Lymphatic mapping and sentinel node detection in gynecologic malignancies of the lower genital tract.

Authors:  Michael Frumovitz; Pedro T Ramirez; Charles Levenback
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

Review 2.  Sentinel node dissection in vulvar cancer.

Authors:  Amy A Hakim; Keith Y Terada
Journal:  Curr Treat Options Oncol       Date:  2006-03

3.  The prognostic significance of micrometastases in node-negative squamous cell carcinoma of the vulva.

Authors:  G V Narayansingh; I D Miller; M Sharma; C J Welch; L Sharp; D E Parkin; M E Cruickshank
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.